Raw Liothyronine sodium (T3) powder Manufacturers & Suppliers - Factory

Raw Liothyronine Sodium (T3) powder (55-06-1)

November 8, 2018
SKU: 55-06-1
5.00 out of 5 based on 1 customer rating

Liothyronine is a synthetic form of thyroid hormone (T3) used to treat hypothyroidism and myxedema coma. It is also used as an augmentation strategy in treating Major Depressive Disorder when used in combination with antidepressants.

 


Status: In Mass Production
Unit: 25kg/Drum

Raw Liothyronine Sodium (T3) powder (55-06-1) video

 

Raw Liothyronine Sodium (T3) powder (55-06-1) Description

Raw Liothyronine Sodium (T3) powder is a synthetic of one of the two hormones made by the thyroid gland, triiodothyronine. It is used for treating individuals who are hypothyroid (do not produce enough thyroid hormones). Thyroid hormones increase the metabolism (activity) of all cells in the body. In the fetus, newborn infant and child, thyroid hormones promote growth and development of tissues. In adults, thyroid hormones help to maintain the function of the brain, the use of food by the body, and body temperature. It also used to treat other types of thyroid problems (such as certain types of goiters, thyroid cancer). It can also be used to test for certain types of thyroid disease.The FDA approved liothyronine in May 1956.

 

Raw Liothyronine Sodium (T3) powder (55-06-1) Specifications

Product Name Raw Liothyronine Sodium (T3) powder
Chemical Name 5-Triiodo-L-thyronine sodium salt, sodium salt (1:1), 5-diiodo- L-Tyrosine
Brand Name Cytomel, Triostat
Drug Class cytochrome P450 inhibitor, Ca antagonist, anesthetic (local)
CAS Number 55-06-1
InChIKey SBXXSUDPJJJJLC-YDALLXLXSA-M
Molecular Formula C15H11I3NNaO4
Molecular Weight 672.96
Monoisotopic Mass 672.772 g/mol
Melting Point  205 °C (dec.)(lit.)
Freezing Point No date available
Biological Half-Life about 2-1/2 days
Color White to Pale Brown
Solubility  4 M NH4OH in methanol: 125 g/5mL, clear, yellow-brown
Storage Temperature  2-8°C
Application Used to treat an underactive thyroid (hypothyroidism)

 

What is Raw Liothyronine Sodium (T3) powder (55-06-1)?

Raw Liothyronine Sodium (T3) powder is a synthetic of one of the two hormones made by the thyroid gland, triiodothyronine. It is used for treating individuals who are hypothyroid (do not produce enough thyroid hormones). Thyroid hormones increase the metabolism (activity) of all cells in the body. In the fetus, newborn infant and child, thyroid hormones promote growth and development of tissues. In adults, thyroid hormones help to maintain the function of the brain, the use of food by the body, and body temperature. It also used to treat other types of thyroid problems (such as certain types of goiters, thyroid cancer). It can also be used to test for certain types of thyroid disease.

Raw Liothyronine Sodium (T3) powder (55-06-1)Dosage

Recommended Dosage for Hypothyroidism

Adults

The recommended starting dosage is 25 mcg orally once daily. Increase the dose by 25 mcg daily every 1 or 2 weeks, if needed. The usual maintenance dose is 25 mcg to 75 mcg once daily.

For elderly patients or patients with underlying cardiac disease, start with CYTOMEL 5 mcg once daily and increase by 5 mcg increments at the recommended intervals.

Serum TSH is not a reliable measure of CYTOMEL dose adequacy in patients with secondary or tertiary hypothyroidism and should not be used to monitor therapy. Use the serum T3 level to monitor adequacy of therapy in this patient population.

Pediatric Patients

The recommended starting dosage is 5 mcg once daily, with a 5 mcg increase every 3 to 4 days until the desired response is achieved. Infants a few months old may require 20 mcg once daily for maintenance. At 1 year of age, 50 mcg once daily may be required. Above 3 years of age, the full adult dosage may be necessary [see Use in Specific Populations (8.4)].

Newborns (0 to 3 months) at Risk for Cardiac Failure:

Consider a lower starting dose in infants at risk for cardiac failure. Increase the dose as needed based on clinical and laboratory response.

Pediatric Patients at Risk for Hyperactivity:

To minimize the risk of hyperactivity in pediatric patients, start at one-fourth the recommended full replacement dose, and increase on a weekly basis by one-fourth the full recommended replacement dose until the full recommended replacement dose is reached.

Pregnancy

Pre-existing Hypothyroidism: Thyroid hormone dose requirements may increase during pregnancy. Measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at minimum, during each trimester of pregnancy. In patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. For patients with serum TSH above the normal trimester-specific range, increase the dose of thyroid hormone and measure TSH every 4 weeks until a stable dose is reached and serum TSH is within the normal trimester-specific range. Reduce thyroid hormone dosage to pre-pregnancy levels immediately after delivery and measure serum TSH levels 4 to 8 weeks postpartum to ensure thyroid hormone dose is appropriate.

Recommended Dosage for TSH Suppression in Well-Differentiated Thyroid Cancer

The dose of CYTOMEL should target TSH levels within the desired therapeutic range. This may require higher doses, depending on the target level for TSH suppression.

Recommended Dosage for Thyroid Suppression Test

The recommended dose is 75 mcg to 100 mcg daily for 7 days, with radioactive iodine uptake being determined before and after the 7 day administration of CYTOMEL. If thyroid function is normal, the radioiodine uptake will drop significantly after treatment. A 50% or greater suppression of uptake indicates a normal thyroid-pituitary axis.

Switching from Levothyroxine to CYTOMEL

CYTOMEL has a rapid onset of action and residual effects of the other thyroid preparation may persist for the first several weeks after initiating CYTOMEL therapy. When switching a patient to CYTOMEL, discontinue levothyroxine therapy and initiate CYTOMEL at a low dosage. Gradually increase the CYTOMEL dose according to the patient’s response.

Monitoring TSH and Triiodothyronine (T3) Levels

Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation. Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of CYTOMEL may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors.

Adults

In adult patients with primary hypothyroidism, monitor serum TSH periodically after initiation of the therapy or any change in dose. To check the immediate response to therapy before the TSH has had a chance to respond or if your patient’s status needs to be assessed prior to that point, measurement of total T3 would be most appropriate. In patients on a stable and appropriate replacement dose, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient’s clinical status.

Pediatrics

In pediatric patients with hypothyroidism, assess the adequacy of replacement therapy by measuring serum TSH and T3 levels. For pediatric patients three years of age and older, the recommended monitoring is every 3 to 12 months thereafter, following dose stabilization until growth and puberty are completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals.

While the general aim of therapy is to normalize the serum TSH level, TSH may not normalize in some patients due to in utero hypothyroidism causing a resetting of pituitary-thyroid feedback. Failure of the serum TSH to decrease below 20 IU per liter after initiation of CYTOMEL therapy may indicate the child is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of CYTOMEL.

Secondary and Tertiary Hypothyroidism

Monitor serum T3 levels and maintain in the normal range.

Raw Liothyronine Sodium (T3) powder (55-06-1) Uses

Liothyronine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally made by the thyroid gland. Liothyronine is a man-made form of thyroid hormone. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone helps you stay healthy. For children, having enough thyroid hormone helps them grow and learn normally.

This medication is also used to treat other types of thyroid problems (such as certain types of goiters, thyroid cancer). It can also be used to test for certain types of thyroid disease.

Buy Liothyronine Sodium (T3) powder from Buyaas.com

Cooperate with us, we can do at least:
1. Our products are produced under cGMP and the quality can be tracked.
2. The purity are Guaranteed no less than 98%. COA; HPLC; HNMR test reports can be provided.
3. Our supply ability is very stable and schedule mass production regularly.
4. We have rich experience in serving high-end markets all over the world.
5. Cooperate with our factory directly, you can reduce your cost.

 


=

References & product citations

The Ultimate Guide to Liothyronine sodium/T3 for Bodybuilding